Project Grant R43AR081768
Award Date
7/1/22
Completion Date
8/31/23
Dollars Obligated
$548K
Awardee
Praeventix LLC (NLSMGTKWQR16)
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Exton, PA 19341, USA
Similar Awards
This federal Project Grant award of $1,587,553 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development and characterization of novel, central nervous system (CNS)-penetrant 5-HT3 receptor antagonists as potential treatments for neuropathic pain. The primary awardee, The Washington University in St. Louis, is collaborating with the University of Health Sciences and Pharmacy in St. Louis...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $603,406 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Research Triangle Institute (RTI International) to develop GPR139 antagonists for enhancing the analgesic efficacy of opioid medications. The project aims to optimize the potency, selectivity, and drug-like properties of GPR139 antagonist compounds through medicinal chemistry and in vitro...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $340,685 to Serentrix LLC, located in Exton, PA, to develop a novel topically applied small molecule TRPV1 antagonist for the treatment of cutaneous burn pain. The research aims to demonstrate that blocking the TRPV1 pain receptor on the skin can significantly ameliorate burn-related pain. The award period runs from August...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,325,500 to develop novel PAC1 receptor antagonists for the treatment of medication overuse headache (MOH). The project aims to leverage a collaborative research effort between the Pradhan, Katritch, and Majumdar labs to identify and characterize promising lead compounds targeting the PAC1 receptor, which plays a key...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $172,700 Project Grant (CFDA 93.846 Arthritis, Musculoskeletal and Skin Diseases Research) to the University of California, Irvine to develop and characterize cell-penetrating botulinum protease variants that can inhibit neurotransmitter release and immune cell signaling in skin. The goal is to create a new topical therapeutic strategy to regulate inflammation in skin diseases like psoriasis and atopic...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $169,560.00 to support a 5-year research project focused on characterizing the cutaneous opioid circuitry and its role in regulating skin inflammation and sensory perception. The primary objectives are to: Identify the cellular sources of the endogenous opioid enkephalin and its function in...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), is focused on investigating the role of Staphylococcus aureus-induced itch and neuro-immune signaling in driving skin inflammation and atopic dermatitis. The $100,138 award, spanning from August 1, 2024 to July 31, 2026, will support research at Harvard Medical School to: 1) define the...
This SBIR Phase I award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to develop a novel topical therapeutic for the treatment of psoriasis. The key objectives are to: 1) characterize the therapeutic efficacy of the new treatment in a mouse model of psoriasis, 2) develop a topical drug product formulation and test its...
This Project Grant awarded by the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to reverse the disrupted developmental sterol biosynthesis caused by prescription medications. The $230,250 award supports research to explore treatments for Smith-Lemli-Opitz Syndrome (SLOS), a developmental disorder resulting from compound heterozygous mutations in the DHCR7 gene that disrupt cholesterol...
This federal Project Grant award, with an ID of DP2AR085223, was issued by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $1,656,000 grant, awarded on September 4, 2024, supports research at the Scripps Research Institute in La Jolla, CA to investigate the regulation of inflammation by nociception (sensory perception of pain or other unpleasant stimuli). The research aims to uncover how endogenous opioid...